Likely active: new fund Jan 2023 Verified 4 Nov 2026
Abingworth
Transatlantic life sciences investor, investing since 1987, that funds biopharma companies from seed through clinical development, and runs a clinical co-development strategy funding late-stage drug programmes.
- Type
- VC firm
- Location
- London, United Kingdom
- Stages
- Seed, Series A, Series B, Growth, Late stage
- Backs
- Biotech and pharma
- Sectors
- Healthtech and life sciences, Biotech
- Fund size / AUM
- Abingworth Bioventures 8 $466m; Clinical Co-Development Fund 2 $466m; CCD Co-Investment Fund $356m
- Latest fund or filing
- 1 Jan 2023
- Website
- www.abingworth.com
Contacts on file
For Abingworth, the paid file holds: 8 named decision-makers with roles; firm contact email (domain checked); check size; LinkedIn page.
Get UK Complete, $149 Free sample
One-time payment. No subscription. No account.
Sources
- www.abingworth.com/
- www.abingworth.com/team
- www.abingworth.com/contact
- www.abingworth.com/about
- www.abingworth.com/strategy
- www.abingworth.com/portfolio
Last checked 4 Nov 2026. Is something wrong? Tell us.
Appears in 26 lists
Biotech investors in London (42)Series B investors in the UK (54)Series B biotech investors (73)Biotech investors in the UK (92)Growth-stage biotech investors (109)Healthtech investors in London (113)Growth-stage investors in the UK (137)Venture capital firms in London (149)Series A biotech investors (153)Series A investors in the UK (154)Series B healthtech investors (160)Venture capital firms in the UK (192)Healthtech investors in the UK (194)Startup investors in London (239)Seed investors in the UK (295)Seed biotech investors (300)Growth-stage healthtech investors (316)Series B investors (339)Series A healthtech investors (401)Startup investors in the UK (416)Biotech investors (484)Growth-stage investors (705)Seed healthtech investors (800)Series A investors (864)Healthtech investors (1,207)Seed investors (1,892)